GlobeNewswireMoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology CongressOct 11, 2023more_vert
Business WireIncyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) CongressSep 29, 2023more_vert
Gulf TimesHMC Dermatology and Venereology Department awarded 36-month QNRF research grant| Gulf TimesFeb 7more_vert
The PeninsulaHMC sets international standards at dermatology subspecialty clinicsSep 9, 2023Fazeena SaleemBy Fazeena Saleemmore_vert
GlobeNewswirePhase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology CongressOct 4, 2023more_vert